These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 38672492)

  • 21. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.
    Foglia B; Sutti S; Cannito S; Rosso C; Maggiora M; Casalino A; Bocca C; Novo E; Protopapa F; Ramavath NN; Provera A; Gambella A; Bugianesi E; Tacke F; Albano E; Parola M
    Front Immunol; 2024; 15():1342404. PubMed ID: 38469298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
    Burmeister Y; Weyer K; Dörre A; Seilheimer B
    Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autophagy, Ferroptosis, Apoptosis and Pyroptosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Zhao S; Guo Y; Yin X
    Front Biosci (Landmark Ed); 2024 Jan; 29(1):30. PubMed ID: 38287834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Backer S; Khanna D
    Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatic inflammation and fibrosis are profiles related to mid-term mortality in biopsy-proven MASLD: A multicenter study in Japan.
    Tsutsumi T; Kawaguchi T; Fujii H; Kamada Y; Takahashi H; Kawanaka M; Sumida Y; Iwaki M; Hayashi H; Toyoda H; Oeda S; Hyogo H; Morishita A; Munekage K; Kawata K; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Ueda S; Aishima S; Nakajima A; Okanoue T
    Aliment Pharmacol Ther; 2024 Jun; 59(12):1559-1570. PubMed ID: 38651312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance.
    Hutchison AL; Tavaglione F; Romeo S; Charlton M
    J Hepatol; 2023 Dec; 79(6):1524-1541. PubMed ID: 37730124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Τ cell-mediated adaptive immunity in the transition from metabolic dysfunction-associated steatohepatitis to hepatocellular carcinoma.
    Papadopoulos G; Giannousi E; Avdi AP; Velliou RI; Nikolakopoulou P; Chatzigeorgiou A
    Front Cell Dev Biol; 2024; 12():1343806. PubMed ID: 38774646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of invariant natural killer T cells by lipid excess promotes tissue inflammation, insulin resistance, and hepatic steatosis in obese mice.
    Wu L; Parekh VV; Gabriel CL; Bracy DP; Marks-Shulman PA; Tamboli RA; Kim S; Mendez-Fernandez YV; Besra GS; Lomenick JP; Williams B; Wasserman DH; Van Kaer L
    Proc Natl Acad Sci U S A; 2012 May; 109(19):E1143-52. PubMed ID: 22493234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?
    Kasprzak-Drozd K; Niziński P; Kasprzak P; Kondracka A; Oniszczuk T; Rusinek A; Oniszczuk A
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the Adipose Tissue-Liver-Gut Microbiota Crosstalk to Cure MASLD.
    Gabbia D; De Martin S
    Biology (Basel); 2023 Nov; 12(12):. PubMed ID: 38132297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation.
    Kjærgaard K; Daugaard Mikkelsen AC; Landau AM; Eriksen PL; Hamilton-Dutoit S; Magnusson NE; Thomsen MB; Chen F; Vilstrup H; Mookerjee RP; Bay-Richter C; Thomsen KL
    JHEP Rep; 2024 Mar; 6(3):100992. PubMed ID: 38415019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive meta-analysis reveals distinct gene expression signatures of MASLD progression.
    Piras IS; DiStefano JK
    Life Sci Alliance; 2024 Jun; 7(6):. PubMed ID: 38565287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
    Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
    Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma.
    Ha S; Wong VW; Zhang X; Yu J
    Gut; 2024 Jun; ():. PubMed ID: 38950910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A natural language processing algorithm accurately classifies steatotic liver disease pathology to estimate the risk of cirrhosis.
    Sherman MS; Challa PK; Przybyszewski EM; Wilechansky RM; Uche-Anya EN; Ott AT; McGoldrick J; Goessling W; Khalili H; Simon TG
    Hepatol Commun; 2024 Apr; 8(4):. PubMed ID: 38551386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ablation of IFNγ in myeloid cells suppresses liver inflammation and fibrogenesis in mice with hepatic small heterodimer partner (SHP) deletion.
    Zhu L; Litts B; Wang Y; Rein JA; Atzrodt CL; Chinnarasu S; An J; Thorson AS; Xu Y; Stafford JM
    Mol Metab; 2024 May; 83():101932. PubMed ID: 38589002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma.
    Rivera-Esteban J; Muñoz-Martínez S; Higuera M; Sena E; Bermúdez-Ramos M; Bañares J; Martínez-Gomez M; Cusidó MS; Jiménez-Masip A; Francque SM; Tacke F; Minguez B; Pericàs JM
    Clin Gastroenterol Hepatol; 2024 Apr; ():. PubMed ID: 38604295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis regulation by the inflammasome signaling pathway.
    Negash AA; Gale M
    Immunol Rev; 2015 May; 265(1):143-55. PubMed ID: 25879290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The double roles of T cell-mediated immune response in the progression of MASLD.
    Li Z; Wang S; Xu Q; Su X; Wang Y; Wang L; Zhang Y
    Biomed Pharmacother; 2024 Apr; 173():116333. PubMed ID: 38479177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apelin and the gut microbiome: Potential interaction in human MASLD.
    Effenberger M; Grander C; Hausmann B; Enrich B; Pjevac P; Zoller H; Tilg H
    Dig Liver Dis; 2024 Jun; 56(6):932-940. PubMed ID: 38087672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.